CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
